Our Business

DVP EU markets and sells Dechra’s products in 18 countries: Austria, Belgium, Bosnia-Hertzegovina, Croatia, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Poland, Portugal, Slovenia, Spain, Sweden and the UK. DVP EU represented 45.1% of Group revenue in the 2023 financial year.

In total, DVP EU employs 561 people as field-based sales representatives, marketing professionals, in-house veterinarians, field veterinarians, and technical support staff. Inventory is managed through a central distribution centre in Uldum, Denmark.

Products are sold across all key categories of Companion Animal Products (CAP), Equine and Food producing Animal Products (FAP). DVP EU also markets a range of specialist, therapeutic and maintenance pet diets, branded Specific™.

DVP International was established as a separate commercial division in 2017, with the aim of further developing Dechra’s global brand and product offering. It markets and sells Dechra’s veterinary products in Australia, New Zealand, Brazil, Serbia and South Korea through our own legal entities and via distributors to other countries worldwide.  

DVP International represented 11.4% of Group revenue in the 2023 financial year and has a total of 385 employees.

DVP ANZ manufactures, markets and sells branded non-proprietary prescription and other related companion animal products in Australia and New Zealand. DVP Brazil predominately manufactures, markets and sells vaccines in Brazil, other South American markets and some Asian countries.  

The products sold by DVP International vary significantly by country, largely due to the different rates at which the Companion Animal Product (CAP) market is developing in each territory.

DVP NA markets and sells Dechra’s veterinary products in Canada, Mexico and the US via our own legal entities and in other Central American countries via distributors.

DVP NA represented 43.5% of Group revenue in the 2023 financial year and has a total of 295 employees consisting of field-based sales representatives, marketing professionals, in-house veterinarians, field veterinarians, technical support staff and a customer service team.

The US business is located in Kansas City, at the heart of the ‘Animal Health Corridor’, an area recognised globally for its concentration of animal health businesses. There is also an additional office in Portland, Maine where part of the Product Development is based and a number of tele-sales.

DVP US predominently markets CAP and Equine medicines. Following the acquisition of Med-Pharmex in August 2022, it also now sells a small range of FAP. DVP Canada and DVP Mexico both market CAP and Equine medicines, whilst the latter also sells FAP and exports to Central American countries.

The Product Development (PD) team develops Dechra’s own branded veterinary product portfolio of novel, generic and generic plus pharmaceuticals and related medical products. The Regulatory Affairs (RA) team obtains licences for our products, manages post approval adverse event reporting, periodic product renewals and other activities required to maintain the product licences in every country that we operate.

At the end of the 2023 financial year, a total of 228 people worked in our PDRA team at various locations globally. The Product Development team run in field clinical trials and formulate at three laboratories based at our manufacturing facilities in the UK, Netherlands and Croatia.  The team includes highly qualified academics, veterinarians, formulation chemists, pharmacists, analysts, clinical trial managers and product development managers.

The PDRA team also includes a number of employees who joined the Group following the acquisition of Piedmont Animal Health, Inc in July 2022. 

DPM&S produces approximately 50% of Dechra’s pharmaceuticals across our eight manufacturing sites, with the remaining 50% managed through external supply relationships. It’s objectives are to produce Dechra’s product range efficiently and to the highest quality standards maintaining a reliable supply chain and to contribute profit to the business through third party manufacturing.

Our manufacturing sites at Skipton, Bladel and Zagreb also include Pharmaceutical Development, Quality Control (QC) and Stability Testing and Validation Laboratories.

Skipton, UK
The site at Skipton offers a comprehensive range of manufacturing and packing services, principally for CAP. It is a centre of excellence in solid forms for tablets and capsules, liquids, creams, ointment products and terminal sterilisation.

Bladel, the Netherlands
The site at Bladel manufactures water soluble powder and premix products for food producing animals in large-scale batches. It is also a centre for aseptic filling and for sterile injectables for both FAP and CAP.

Zagreb, Croatia
Produces and develops egg based vaccines in addition to liquids in various scales and formats. It is currently being expanded to be a second source of solid dose tablets.

Fort Worth, Texas USA
This site manufactures solid dose, liquids, creams and ointments for the North American market.

Londrina, Brazil
Produces a wide range of vaccines for multi species predominately for South America and selected export markets.

Sydney, Australia
This site produces a broad portfolio of dosage types for the Australian and New Zealand markets including tablets and liquids.

Pomona, California USA
Med-Pharmex site acquired in August 2022. It has expertise in topical, oral and certain injectible products.